Marie – Interview 25
Marie was diagnosed with chronic lymphocytic leukaemia in 1992. She was recently invited to take part in a clinical trial of a new monoclonal antibody. At first she thought she would take part but after reading all the details decided against it.
On her return from living in Africa in 1989 Marie developed pains which her GP attributed to the change in climate and possible rheumatism. A year later a pain in her groin prompted the GP to do a blood test. Marie was referred to a consultant who told her it was chronic lymphocytic leukaemia. She was shocked and assumed it meant she would die but was told that her disease had been caught early so would be monitored with regular blood tests and she should get on with her life.
She spent two years watching and waiting; during which time her symptoms became more troublesome and she began to feel tired. Since then she has had several courses of chemotherapy tablets called chlorambucil, which kept her symptoms under control. Three years ago her body failed to respond to the chlorambucil in the usual way so she was given FluCy (a combination of fludarabine and cyclophosphamide), also in tablet form. She was well again for fourteen months but then began to feel tired, had pains under her arms and a lump formed in her neck and she had no immunity to infections.
Marie’s consultant invited her to take part in a drug company-run clinical trial of a new monoclonal antibody called HuMax-CD20 (ofatumumab). This was a single-arm trial in which every participant would be given the treatment. She tentatively agreed to take part but after reading all the details decided against it. She found the written information provided quite complex and was concerned that the trial was being run by a drug company rather than the hospital. The information said the trial could be stopped at any time if the company felt it had enough information, and that it would not continue to provide the drug after the trial was ended, even if it was working. Marie felt quite angry about the way it was presented.
She advises people to think very carefully whether or not to take part in a trial. She feels staff running trials have a responsibility to be clear about the drawbacks of taking part as well as the advantages. She worries that people may feel under pressure to take part if they see it as a life-line.
Marie has since had further FluCy treatment and is now feeling well again.